Overview Dividends

(MRNA) Moderna - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US60770K1079

Respiratory Vaccines, Latent Vaccines, Oncology Therapeutics, Rare Disease Treatments, Public Health Vaccines

EPS (Earnings per Share)

EPS Growth (3y CAGR): -12.49%
EPS Trend (3y Corr): -32.3%

Last SUE: 0.51σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): -44.58%
Revenue Trend (3y Corr): -51.2%

Last SUE: 0.45σ
Qual. Beats: 0

Risk via 10d forecast
Volatility	67.1%
Value at Risk 5%th	97.3%
Relative Tail Risk	-11.87%

Reward TTM
Sharpe Ratio	-0.42
Alpha	-56.24

Character TTM
Hurst Exponent	0.467
Beta	1.251
Beta Downside	1.004

Drawdowns 3y
Max DD	88.81%
Mean DD	58.14%
Median DD	57.78%

Description: MRNA Moderna October 30, 2025

Moderna, Inc. (NASDAQ: MRNA) is a biotech firm that commercializes messenger-RNA (mRNA) medicines across respiratory, latent, enteric, public-health, and bacterial-disease vaccine categories, as well as oncology and rare-disease therapeutics. Its pipeline spans COVID-19, RSV, CMV, EBV, HSV, VZV, HIV, norovirus, Zika, Nipah, mpox, Lyme disease, and a suite of individualized cancer vaccines and enzyme-replacement products for metabolic disorders.

In its most recent quarter (Q2 2024), Moderna reported revenue of approximately $5.1 billion, driven primarily by Spikevax sales of $1.2 billion and a newly launched RSV vaccine that contributed $250 million. The company ended the period with a cash-and-short-term-investments balance of $8.5 billion and R&D expenditures of $1.8 billion, reflecting continued investment in Phase 3 CMV and EBV vaccine programs and the expansion of its oncology pipeline.

Key macro drivers include accelerating adoption of mRNA technology beyond COVID-19, robust U.S. and EU government funding for pandemic preparedness, and competitive pressure from peers such as Pfizer/BioNTech and CureVac, which together shape pricing dynamics and market share. For a deeper, data-rich analysis of how these factors may affect Moderna’s valuation, a quick look at ValueRay’s platform can provide useful context.

MRNA Stock Overview

Market Cap in USD	9,753m
Sub-Industry	Biotechnology
IPO / Inception	2018-12-07
Return 12m vs S&P 500	-45.3%
Analyst Rating	3.22 of 5

MRNA Dividends

Currently no dividends paid

MRNA Growth Ratios

Metric	Value
CAGR 3y	-48.38%
CAGR/Max DD Calmar Ratio	-0.54
CAGR/Mean DD Pain Ratio	-0.83
Current Volume	8244.6k
Average Volume	9582.3k

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-3.12b TTM) > 0 and > 6% of Revenue (6% = 133.3m TTM)

FCFTA -0.22 (>2.0%) and ΔFCFTA 3.09pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 221.4% (prev 147.6%; Δ 73.74pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.16 (>3.0%) and CFO -1.98b > Net Income -3.12b (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 3.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (390.0m) change vs 12m ago -2.26% (target <= -2.0% for YES)

Gross Margin 11.93% (prev 67.29%; Δ -55.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 15.90% (prev 31.99%; Δ -16.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -393.1 (EBITDA TTM -2.94b / Interest Expense TTM 8.00m) >= 6 (WARN >= 3)

Altman Z'' 6.33

(A) 0.41 = (Total Current Assets 6.60b - Total Current Liabilities 1.68b) / Total Assets 12.13b

(B) 0.66 = Retained Earnings (Balance) 8.05b / Total Assets 12.13b

(D) 2.88 = Book Value of Equity 8.08b / Total Liabilities 2.81b

Total Rating: 6.33 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 26.03

1. Piotroski 1.50pt = -3.50

2. FCF Yield -44.52% = -5.0

3. FCF Margin data missing

4. Debt/Equity 0.08 = 2.50

5. Debt/Ebitda 0.14 = 2.49

6. ROIC - WACC (= -43.86)% = -12.50

7. RoE -31.40% = -2.50

8. Rev. Trend -51.23% = -3.84

9. EPS Trend -32.26% = -1.61

What is the price of MRNA shares?

As of November 18, 2025, the stock is trading at USD 24.76 with a total of 8,244,600 shares traded.
Over the past week, the price has changed by +0.00%, over one month by -4.81%, over three months by -11.85% and over the past year by -37.33%.

Is MRNA a buy, sell or hold?

Moderna has received a consensus analysts rating of 3.22. Therefor, it is recommend to hold MRNA.

Strong Buy: 5
Buy: 1
Hold: 17
Sell: 3
Strong Sell: 1

What are the forecasts/targets for the MRNA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	39.2	58.1%
Analysts Target Price	39.2	58.1%
ValueRay Target Price	15.3	-38.2%

MRNA Fundamental Data Overview November 17, 2025

Market Cap USD = 9.75b (9.75b USD * 1.0 USD.USD)
P/E Forward = 32.4675
P/S = 4.3695
P/B = 1.0374
Beta = 1.111
Revenue TTM = 2.22b USD
EBIT TTM = -3.15b USD
EBITDA TTM = -2.94b USD
Long Term Debt = 734.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 48.0m USD (from shortTermDebt, last quarter)
Debt = 734.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -399.0m USD (from netDebt column, last quarter)
Enterprise Value = 5.98b USD (9.75b + Debt 734.0m - CCE 4.50b)
Interest Coverage Ratio = -393.1 (Ebit TTM -3.15b / Interest Expense TTM 8.00m)
FCF Yield = -44.52% (FCF TTM -2.66b / Enterprise Value 5.98b)
FCF Margin = -119.9% (FCF TTM -2.66b / Revenue TTM 2.22b)
Net Margin = -140.3% (Net Income TTM -3.12b / Revenue TTM 2.22b)
Gross Margin = 11.93% ((Revenue TTM 2.22b - Cost of Revenue TTM 1.96b) / Revenue TTM)
Gross Margin QoQ = 0.79% (prev 16.20%)
Tobins Q-Ratio = 0.49 (Enterprise Value 5.98b / Total Assets 12.13b)
Interest Expense / Debt = 1.09% (Interest Expense 8.00m / Debt 734.0m)
Taxrate = -6.95% (negative due to tax credits) (13.0m / -187.0m)
NOPAT = -3.36b (EBIT -3.15b * (1 - -6.95%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.93 (Total Current Assets 6.60b / Total Current Liabilities 1.68b)
Debt / Equity = 0.08 (Debt 734.0m / totalStockholderEquity, last quarter 9.33b)
Debt / EBITDA = 0.14 (negative EBITDA) (Net Debt -399.0m / EBITDA -2.94b)
Debt / FCF = 0.15 (negative FCF - burning cash) (Net Debt -399.0m / FCF TTM -2.66b)
Total Stockholder Equity = 9.92b (last 4 quarters mean from totalStockholderEquity)
RoA = -25.68% (Net Income -3.12b / Total Assets 12.13b)
RoE = -31.40% (Net Income TTM -3.12b / Total Stockholder Equity 9.92b)
RoCE = -29.51% (EBIT -3.15b / Capital Employed (Equity 9.92b + L.T.Debt 734.0m))
RoIC = -33.89% (negative operating profit) (NOPAT -3.36b / Invested Capital 9.92b)
WACC = 9.97% (E(9.75b)/V(10.49b) * Re(10.63%) + D(734.0m)/V(10.49b) * Rd(1.09%) * (1-Tc(-0.07)))
Discount Rate = 10.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.63%
Fair Price DCF = unknown (Cash Flow -2.66b)
EPS Correlation: -32.26 | EPS CAGR: -12.49% | SUE: 0.51 | # QB: 0
Revenue Correlation: -51.23 | Revenue CAGR: -44.58% | SUE: 0.45 | # QB: 0

Additional Sources for MRNA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle